Scientiae Radices 5(3) 190-194 (2026)

Mini-review

A mini review on the recent progress about the synthesis of active pharmaceutical Ingredients (APIs)

Abolghasem Beheshti[1], Ali Ghalibafi[2], Parvaneh Pakravan[2]*

1. Department of Chemistry, Payame Noor University (PNU), P. O. Box 19395-3697, Tehran, Iran
2. Department of Chemistry, Za.C., Islamic Azad University, Zanjan, Iran.

* Correspondence to: pakravanparvaneh@yahoo.com, parvaneh.pakravan@iau.ac.ir

Abstract

The pharmaceutical industry is undergoing a critical transition from traditional batch manufacturing toward sustainable, continuous, and Green-by-Design processes for API synthesis. This review explores advanced methodologies, including biocatalysis, multi-enzyme cascades, and continuous flow chemistry, which significantly enhance atom economy, selectivity, and environmental compatibility. While these technologies offer superior efficiency and reduced waste, their industrial implementation faces substantial hurdles. Key challenges include the complex engineering of scale-up, specifically regarding heat and mass transfer control, the economic viability of enzymatic processes, and the necessity for real-time pharmaceutical analysis to ensure product purity. By integrating advanced synthetic strategies with rigorous sustainability metrics and robust analytical workflows, the industry can bridge the gap between laboratory innovation and large-scale production. Ultimately, overcoming these technical and economic barriers is essential for developing a more efficient, resilient, and environmentally responsible drug manufacturing landscape.

Keywords: API Synthesis, Review Articles, Drug manufacturing, artificial inteligence, industrial challenges

Received: 2026.08.06
Accepted: 2026.09.18
Published: 2026.09.25

1. Introduction

The synthesis of Active Pharmaceutical Ingredients (APIs) [1,2] stands as the cornerstone of modern medicine, serving as the fundamental bridge between chemical innovation and therapeutic efficacy. The precision with which these complex molecules are constructed dictates not only the quality and safety of the final drug product but also the economic viability of pharmaceutical manufacturing [3,4]. In recent years, the scientific community has intensified its efforts to move beyond traditional, often inefficient, batch-processing methodologies toward more sophisticated, sustainable, and high-efficiency synthetic routes [5,6]. A transformative frontier in this endeavor is the integration of nanotechnology; the deployment of nano-engineered materials and heterogeneous nanocatalysts has revolutionized the

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i3a05

field by providing unprecedented control over reaction selectivity, surface area, and catalytic activity, thereby minimizing waste and optimizing molecular architecture [7,8].

The urgency of refining these synthetic paradigms was starkly highlighted by the global COVID-19 pandemic, which exposed critical vulnerabilities in the global pharmaceutical supply chain [9]. This unprecedented health crisis underscored a profound necessity: the ability to transition from discovery to large-scale manufacturing with rapidity [10]. The pandemic served as a catalyst for a paradigm shift, emphasizing that readiness for future biological threats depends heavily on our capacity for *rapid-response manufacturing*. Ensuring preparedness for subsequent pandemics [11,12] requires the establishment of robust, agile, and highly scalable synthetic platforms capable of producing strategic medicines on demand. This necessitates proactive planning for the rapid synthesis and characterization of strategic APIs or formulated drugs [13,14] which are essential for antiviral, antibiotic, and immunomodulatory interventions to prevent the catastrophic delays observed in recent years, especially by artificial intelligence (AI) technology [15,16].

In light of these multifaceted challenges ranging from the need for greener, nano-enabled catalytic processes to the strategic imperative of pandemic preparedness and rapid-response synthesis, a comprehensive understanding of the current landscape is essential. Consequently, this mini-review aims to synthesize and critically analyze recent high-impact review articles focusing on the latest advancements in API synthesis. By mapping the progression from conventional methods to cutting-edge, rapid-scale technologies, this article provides a strategic overview of how modern synthetic chemistry is evolving to meet both routine medicinal needs and the urgent demands of global health security.

2. Advanced Approaches in Sustainable Synthesis

The transition towards sustainable API manufacturing is driven by a synergy of innovative chemical, biological, and engineering methodologies. A fundamental paradigm shift is the adoption of "Green-by-Design" strategies, where sustainability is integrated from the onset of route development using reliable metrics like Process Mass Intensity (PMI) and Life Cycle Assessment (LCA) to minimize environmental footprints [17]. In terms of reaction media, the move away from organic solvents towards aqueous micellar conditions has revolutionized catalysis, offering high yields and easier product isolation [18]. Furthermore, the implementation of Multicomponent Reactions (MCRs) proposed by Kar et al, has significantly enhanced synthetic efficiency by constructing complex molecules in fewer steps [19]. Biocatalysis has emerged as a cornerstone of this evolution; recent advances in protein engineering and directed evolution allow for the development of highly selective enzymes that enable shorter and more sustainable routes compared to traditional chemical protocols [20,21]. These enzymatic processes, especially when utilized in multi-enzyme cascades, offer advantages such as improved equilibrium shifts and reduced solvent requirements [22] (Table 1).

Table 1. Summary Table of Advanced API Synthesis Technologies

Technology Category	Key Methodologies / Tools	Primary Advantages	Core Focus / Reference
Sustainability Metrics	PMI, LCA, Green-by-Design	Target setting, measuring environmental footprint	Process optimization/Rose et al. [17]
Green Reaction Media	Micellar catalysis, Aqueous media	Reduction of organic solvents, waste minimization	Sustainability & Yield/ Compagno et al. [18]
Synthetic Strategies	MCRs, One-pot, Continuous processing	Atom economy, reduced steps, high efficiency	Synthetic efficiency/ Kar et al. [19]
Biocatalysis	Directed evolution, Enzyme cascades	High selectivity, mild conditions, biodegradability	Greener alternatives [20-22]/ for example
Process Engineering	Continuous Flow, Microreactors	Overcoming scale-up limits, heat/mass transfer	Industrial scalability [7,8,10,11]
Quality Control	Pharmaceutical Analysis (HPLC, GC, XRD)	Ensuring API purity and physicochemical quality	Synthesis-to-analysis workflow [9]

Moreover, the integration of continuous flow biocatalysis addresses classical limitations like enzyme inhibition and difficult scale-ups, providing a practical pathway for industrial-scale production [7, 8]. Beyond the synthesis itself, the manufacturing process must encompass a rigorous pharmaceutical analysis phase including instrumental tests like HPLC and XRD to ensure the final API meets stringent quality and purity standards [9]. Finally, the evolution of these technologies is increasingly moving towards continuous processing and process intensification, which, despite the engineering challenges

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i3a05

of scaling from micro-reactors to industrial plants, represent the future of efficient and environmentally compliant drug manufacturing [10, 11].

3. Challenges in Scaling-up and Industrial Implementation

Despite the transformative potential of green and continuous technologies, several critical bottlenecks impede their seamless transition from laboratory-scale research to large-scale industrial manufacturing. The most prominent challenge lies in the complex engineering of scale-up, particularly when transitioning from micro-reactors to industrial-sized continuous flow systems. Maintaining precise control over heat and mass transfer—which are easily managed at the milligram scale—becomes exponentially more difficult in large-scale reactors, potentially leading to temperature gradients that compromise reaction selectivity and product safety [10, 11]. Furthermore, while biocatalysis offers unparalleled selectivity, the economic viability of using engineered enzymes remains a concern due to high production costs and the necessity for enzyme immobilization to ensure stability and recyclability in long-term continuous processes [4, 7]. The integration of "Green-by-Design" principles also introduces a tension between environmental sustainability and economic profitability; optimizing for a low Process Mass Intensity (PMI) may sometimes require more expensive reagents or complex purification steps that increase the overall cost of the API [1]. Additionally, the implementation of continuous flow synthesis requires a significant reconfiguration of existing batch-oriented pharmaceutical infrastructure, posing a high capital expenditure barrier for many manufacturers [8, 10]. From a quality assurance perspective, ensuring consistent API purity across long production runs is paramount. The integration of real-time analytical tools, as emphasized in the workflow from synthesis to pharmaceutical analysis, is essential to monitor deviations instantaneously and prevent the production of large batches of substandard material [9]. Finally, the complexity of managing multi-enzyme cascades or multicomponent reactions (MCRs) at scale introduces new risks regarding intermediate stability and downstream processing efficiency [3, 6]. Overcoming these multifaceted challenges requires a holistic approach that combines advanced chemical engineering, rigorous economic modeling, and real-time analytical monitoring to ensure that sustainable innovations are both technically robust and commercially competitive in the global pharmaceutical market.

4. Conclusion

In conclusion, the transition toward sustainable API manufacturing represents a fundamental paradigm shift in pharmaceutical science, moving from traditional batch processes to integrated, green, and continuous methodologies. The synergy of biocatalysis, continuous flow chemistry, and multicomponent reactions offers a robust framework for enhancing atom economy and reducing environmental impact through Green-by-Design principles. However, the successful industrial implementation of these technologies remains contingent upon overcoming significant engineering hurdles, particularly regarding heat/mass transfer during scale-up and the economic optimization of enzymatic processes. A holistic approach integrating advanced synthetic routes with real-time pharmaceutical analysis and rigorous sustainability metrics is essential. Ultimately, bridging the gap between laboratory-scale innovation and large-scale industrial production will require continued collaboration between chemical engineers and pharmaceutical scientists to ensure that the next generation of drug manufacturing is not only high-performing but also environmentally resilient and commercially viable.

References

[1] D. Tan, L. Loots, and T. Friščić, 'Towards medicinal mechanochemistry: evolution of milling from pharmaceutical solid form screening to the synthesis of active pharmaceutical ingredients (APIs)' Chem. Commun.vol., 52, no. 50, 7760-7781, 2016.

[2] M. Baumann, and I. R. Baxendale, 'The synthesis of active pharmaceutical ingredients (APIs) using continuous flow chemistry' Beilstein j. org. chem., 11, no. 1, 1194-1219, 2015.

[3] R. Pathak, V. Gaur, H. Sankrityayan, and J. Gogtay, 'Tackling Counterfeit Drugs: The Challenges and Possibilities' Pharmaceutical med., vol. 37, no. 4, 281-290, 2023.

[4] S. A. Siadati, M. A. Ebrahimzadeh, R. Yazdian Robati, and E. Babanezhad, 'How to Manufacture a Drug API? A Simple Scheme from synthesis to analysis' Sci. Rad., vol. 3, no. 2, 89-107, 2024.

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i3a05

[5] K. A. Sanoja-Lopez, E. Nope, and R. Luque, 'Sustainable optimization of pharmaceutical synthesis: applications and benefits of continuous flow chemistry, Green Chem. Lett. Rev., vol. 18, no. 1, 2549732, 2025.
[6] J. R. Sonawane, R. Jundale, and A. A. Kulkarni, 'Continuous flow synthesis of metal nanowires: protocols, engineering aspects of scale-up and applications' Material. Horizon. Vol. 12, no. 2, 364-400, 2025.
[7] R. Taheri-Ledari, and A. Maleki, 'Magnetic nanocatalysts utilized in the synthesis of aromatic pharmaceutical ingredients' New J. Chem., vol. 45, no. 9, 4135-4146, 2021.
[8] S. A. Siadati, R. Yazdian-Robati, M. Ebrahimzadeh, and E. Babanezhad, 'Surface-engineered super-magnetic Fe_3O_4 nanocatalysts for efficient and recyclable synthesis of fentanyl citrate: An integrative experimental and theoretical framework' Curr. Chem. Lett. Vol. 15, no. 3, 545-558, 2026.
[9] L. Ferrazzano, M. Catani, A. Cavazzini, G. Martelli, D. Corbisiero, P. Cantelmi, T. Fantoni, Sustainability in peptide chemistry: current synthesis and purification technologies and future challenges, Green Chem., vol. 24, no. 3, 975-1020, 2022.
[10] E. Bø, I. B. Hovi, D. R. Pinchasik, COVID-19 disruptions and Norwegian food and pharmaceutical supply chains: Insights into supply chain risk management, resilience, and reliability. Sustain. Futures., vol. 5, 100102, 2023.
[11] S. A. Siadati, M. A. Ebrahimzadeh, Hantavirus mitigation: Synergizing AI, ML, DL and human-in-the-loop for drug discovery and prevention, inspired by COVID-19 pandemic experiences, Curr. Chem. Lett., vol. 15, 2026, DOI: 10.5267/j.ccl.2026.6.004.
[12] J. Kaur, and Z. A. Butt, AI-driven epidemic intelligence: the future of outbreak detection and response' Front. Artif. Intell., vol. 8, 1645467, 2025.
[13] G. Wang, H. T. Ang, S. R. Dubbaka, P. O'Neill, and J. Wu, 'Multistep automated synthesis of pharmaceuticals' Trends Chem., vol. 5, no. 6, 432-445, 2023.
[14] M. A. Ebrahimzadeh, S. A. Siadati, 'Why some FT-IR peaks disappear in drug-loaded nanocarriers, polymers, and formulated granules? Unmasking the invisible and the role of AI in spectral interpretation' Curr. Chem. Lett., 2026, DOI: 10.5267/j.ccl.2026.7.006.
[15] C. W. Coley, D. A. Thomas, J. A. Lummiss, J. N. Jaworski, C. P. Breen, V. Schultz, K. F. Jensen, A robotic platform for flow synthesis of organic compounds informed by AI planning. Science, vol. 365, no. 6453, eaax1566, 2019.
[16] S. A. Siadati, M. A. Ebrahimzadeh, 'Human-in-the-Loop Artificial Intelligence in Pharmaceutical Industry: Enhancing Efficiency and Maintaining Oversight' Sci. Rad., vol. 5, no. 2, 102-115, 2026.
[17] H. B. Rose, B. Kosjek, B. M. Armstrong, and S. A. Robaire, 'Green and sustainable metrics: Charting the course for green-by-design small molecule API synthesis' Curr. Res. Green Sustain. Chem., vol. 5, 100324, 2022.
[18] N. Compagno, R. Profeta, A. Scarso, 'Recent advances in the synthesis of active pharmaceutical and agrochemical ingredients in micellar media' Curr. Opinion Green Sustain. Chem., vol. 39, 100729, 2023.
[19] P. Kar, H. Sanderson, K. Roy, E. Benfenati, and J. Leszczynski. 'Green chemistry in the synthesis of pharmaceuticals' Chem. Rev., vol. 122, no. 3, 3637-3710, 2023.
[20] Simic, S., Zukic, E., Schmermund, L., Faber, K., Winkler, C. K., & Kroutil, W. (2021). Shortening synthetic routes to small molecule active pharmaceutical ingredients employing biocatalytic methods. Chemical Reviews, 122(1), 1052-1126.
[21] Santi, M., Sancineto, L., Nascimento, V., Braun Azeredo, J., Orozco, E. V., Andrade, L. H., ... & Santi, C. (2021). Flow biocatalysis: A challenging alternative for the synthesis of APIs and natural compounds. International journal of molecular sciences, 22(3), 990. Abstract
[22] Siedentop, Regine, and Katrin Rosenthal. "Industrially relevant enzyme cascades for drug synthesis and their ecological assessment." International Journal of Molecular Sciences 23, no. 7 (2022): 3605.
[23] Kumar, Vinod, Vasudha Bansal, Aravind Madhavan, Manoj Kumar, Raveendran Sindhu, Mukesh Kumar Awasthi, Parameswaran Binod, and Saurabh Saran. "Active pharmaceutical ingredient (API) chemicals: a critical review of current biotechnological approaches." Bioengineered 13, no. 2 (2022): 4309-4327.
[24] Lovato, Kaitlyn, Patrick S. Fier, and Kevin M. Maloney. "The application of modern reactions in large-scale synthesis." Nature Reviews Chemistry 5, no. 8 (2021): 546-563.
[25] Souza, J. M. D., Galaverna, R., Souza, A. A. D., Brocksom, T. J., Pastre, J. C., Souza, R. O. D., & Oliveira, K. T. D. (2018). Impact of continuous flow chemistry in the synthesis of natural products and active

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i3a05

pharmaceutical ingredients. Anais da Academia Brasileira de Ciências, 90(01 Suppl 2), 1131-1174.

[26] Ötvös, S. B., & Kappe, C. O. (2021). Continuous flow asymmetric synthesis of chiral active pharmaceutical ingredients and their advanced intermediates. Green Chemistry, 23(17), 6117-6138.

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i3a05